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ABSTRACT

This invention relates to a body fluids identification method
and kit. A parallel, multiplex reverse transcription-polymerase chain reaction (RT-PCR) assay forthe definitive identification of body fluids commonly encountered in forensic
casework analysis, namely blood, saliva, semen, and vaginal
secretions. The methodology is based on gene expression
profiling analysis in which the body fluid-specific genes are
identified by detecting the presence of appropriate messenger
RNA species. Gene-specific primers are labeled with fluorescent dyes, separated and subjected to laser induced fluorescence for identification ofbody fluid-specific genes present in
a sample stain.

12 Claims, 1 Drawing Sheet
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Primer Sequences/di:es
5'- 6-FAM- agg atg get tgg cct tta at (Seq ID l)
Y- act gee age ace ttc ate tt (Seq ID 2)
5'-TET- tggatc cct gag gag ggc aga ag (Seq ID 3)
5'- tct tgt·ccc ctg tgg tgg aca tag ca.at {Seq JD 4)
5'- 6-FAM- ctt ctg tag tct cat ctt g (Seq ID 5)
5' - tgg ttg tgg gta tag tgg ttg ttc (Seq ID 6)
5'-6-FAM- gcaaag aga cat cat ggg ta{Seq ID 7)
5' - gee agt caa ace tee ata ate {Seq ID 8}
5' - HEX- gee agg tac aga tgc tgt cgc ag (Seq ID 9)
5'- tta gtg tct tct aca tct egg tct (Seq ID 10)
5'- 6-FAM- gtg agg.agc ctg age gaa cgc (Seq ID ll)
5' - tta gtg cct tct gca tgt tct ctt c (Seq ID 12}
s· -6-FA.t\f- ttc ctg aaa tee tga gtg tt (Seq ID 13)
5'- taa cag gtg cct tga att tt (Seq ID 14)
5'-HEX- gga cca cat ttt ate agg aa (Seq ID 15)
s~ -tag aga aac agg gca tag ga (Seq ID 16)

Figure 1

Size
247bp

177 bp
198 bp
134 bp
153 bp
294 bp

213 bp
235 bp
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MESSENGER RNA PROFILING: BODY
FLUID IDENTIFICATION USING
MULTIPLEX REVERSE
TRANSCRIPTION-POLYMERASE CHAIN
REACTION (RT-PCR)

As more and more tissue-specific genes (mRNAs) are identified for use in the positive identification of body fluids and
tissues of forensic importance, there is an increasing need for
a device or assay system that provides simultaneous and
semi-automatic analysis through a common assay format.
The novel multiplex, parallel assay system of the present
invention provides a common assay format and offers many
advantages over the conventional analysis procedures for
body fluid identification.

This invention claims the benefit of priority from U.S.
Provisional Application Ser. No. 60/545,792 filed Feb. 19,
2004.
10

FIELD OF THE INVENTION

SUMMARY OF THE INVENTION

This invention relates to a ribonucleic acid (RNA) based
assay system and kit for body fluid identification, and in
particular to a novel, multiplex, parallel assay system based
on messenger RNA expressed in human tissue, and to a
method for using the same.

A primary objective of the present invention is to provide
facile identification of the tissue components present in a
body fluid stain.
A second objective of the present invention is to supplant
the battery of serological and biochemical tests currently
employed in the forensic serology laboratory.
A third objective of the present invention is to provide a
common assay format that provides greater specificity in the
identification of body fluids with improved timeliness.
A fourth objective of the present invention is to decrease
sample consumption during analysis of stains containing
body fluids.
A fifth objective of the present invention is to provide
simultaneous and semi-automatic analysis through a common assay format.
A sixth objective of the present invention is to provide a
multiplex analysis of body fluids in an assay format that is
compatible with DNA extraction methodologies.
A seventh objective of the present invention is to provide a
kit that can be used to identify the source of at least four body
fluids from a human being found in a single stain or a mixed
stain.
A preferred method for preparing a multiplex, parallel
assay to identify the source of at least four body fluids from a
human being includes obtaining a sample stain consisting of
a body fluid from a human being, extracting total ribonucleic
acid (RNA) from the sample stain, treating the total RNA with
an enzyme, initiating a reverse-transcriptase (RT) reaction by
treating total RNA with random decamers to produce cDNA,
amplifying the cDNA using gene-specific primers controlling
the size of the amplified cDNA to allow separation by electrophoresis, and identifying body fluid-specific genes present
in the sample as either a single or a mixed stain.
The total RNA is extracted with a denaturing solution, such
as, guanidine isothiocyanate-phenol:chloroform. Then, the
extracted total RNA is precipitated with an organic solvent,
such as, isopropanol. A preferred enzyme, such as, deoxyribonuclease I (DNase I) is used to treat the extracted total
RNA.
The preferred multiplex assay is an octaplex composed of
eight body fluid-specific genes optimized for the detection of
body fluids from four specific body tissues. The fluids
selected from four specific body tissues, are identified as,
blood, saliva, semen and vaginal secretions.
The gene-specific primers are labeled with fluorescent
dyes and are incorporated into a single multiplexed polymerase chain reaction (PCR) and the cDNA is amplified prior
to separation according to size. A preferred method of separation is via capillary electrophoresis. The separated PCR
product is then subjected to laser induced fluorescence for
identification of body fluid-specific genes present in a sample
stain.
Eight body fluid-specific genes are used in a multiplex,
parallel assay and the eight body fluid-specific genes are
selected from the group consisting of: beta-spectrin (SPTB),

15

BACKGROUND AND PRIOR ART
20

Conventional methods of body fluid identification use a
variety oflabor-intensive, technologically diverse techniques
that are performed in a series, not parallel, manner and are
costly in terms of time and consumption of sample. It used to
be standard practice to perform biochemical, serological, and
immunological tests to identify the body fluid(s) comprising
a biological stain. Increasingly, however, classical methods
for body fluid identification have no confirmatory technique
for some frequently encountered body fluids. For example,
there is no definitive test for the presence of saliva or vaginal
secretions, and urine identification can be problematic. The
need exists for a more reliable, efficient assay system to
supplant conventional methods for body fluid identification.
Previous research in the development of a ribonucleic acid
(RNA) based assay system for the identification of body
fluids, included considerations for the use of protein and
messenger RNA (mRNA) since both are expressed in a tissuetype specific manner. However, multiplex analysis of complex protein mixtures, such as those present in body fluid
stains, requires further developments in the field of proteomics. Whereas, with messenger RNA (mRNA), the molecular
intermediate between genetic DNA and expressed protein is
at present, supported by technologies for massively parallel
analysis in the field of genomics.
As reported by B. Alberts, et al. Molecular Biology of the
Cell 3rd ed., Garland Publishing Inc., NY, 1994, a pattern of
gene expression is produced that is unique to each cell type
and is evinced by the presence as well as the relative abundance of specific mRNAs. Each cell type, such as, blood
monocytes, lymphocytes, ejaculated spermatozoa, epithelial
cells lining the oral cavity or epidermal cells, has a unique
pattern of gene expression.
Specific gene expression patterns for saliva were reported
by J. Juusola and J. Ballantyne in February 2002 in a presentation to theAmericanAcademy of Forensic Science (AAFS)
entitled, "The Development of an RNA Based Assay System
for Body Fluid Identification," and in Forensic Science International, Vol. 135 (2003) pages 85-96 ("Messenger RNA
Profiling: a Prototype Method to Supplant Conventional
Methods for Body Fluid Identification"). Semen specific
genes were reported by J. Juusola and J. Ballantyne in "The
Development of an RNA Based Assay System for Body Fluid
Identification," presented toAAFS, February 2002. M. Bauer
and D. Patzelt also identified semen specific genes in an
article, "Protamine mRNA as Molecular Marker for Spermatozoa in Semen Stains," International Journal ofLegal Medicine Vol. 117 (2003)pages 175-179.
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porphobilinogen deaminase (PBGD), statherin (STATH),
histatin 3 (H-1-N3), protamine 1 (PRMl), protamine 2
(PRM2), mucin 4 (MUC4) and human beta-defensin 1
(HBDl)).
The messenger RNA genes for human blood are identified
as beta-spectrin (SPTB) and porphobilinogen deaminase
(PBGD). The messenger RNA genes for vaginal secretions
are identified as mucin 4 (MUC4) and human beta-defensin 1
(HBDl).
A kit is provided for use in preparing a multiplex, parallel
assay to identify the source of at least four body fluids from a
human being, comprising PCR primers pre-selected from 4 or
more of the group consisting of 8 body fluid-specific gene
primers constructed from SPTB, PBGD, STATH, HTN3,
PRMl, PRM2, MUC4, and HBD-1 genes. In the kits, PCR
primers are tagged with fluorescent dyes. It is possible to
redesign primers for one or more of the body fluid-specific
genes and it is understood that the redesigned primers are
within the scope of the present invention.
Further objects and advantages of this invention will be
apparent from the following detailed description and example
of a presently preferred embodiment.

4
TABLE I
BODYFLUIDSPECIFIC GENE:
beta-spectrin
(SPTB)
porphobilinogen
dearninase
(PBGD)
10 statherin
(STATH)
histatin 3
(HTN3)
protarnine 1
(PRMl)
15 protamine 2
(PRM2)
mucin 4 (MUC4)

20

BRIEF DESCRIPTION OF THE DRAWING
25

FIG. 1 shows the sequences of the PCR primers for the
various body fluid specific genes used in the assay.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS
Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The invention provides a multiplex, parallel assay to identify the tissue source for at least four body fluids from a
human being. The first step in the development of the invention is the identification of tissue-specific genes that are
expressed in only one tissue. For example, each tissue type is
comprised of cells that have a unique transcriptome, or gene
expression profile, also known as the messenger ribonucleic
acid (mRNA). The collection of genes that are expressed
within the constellation of differentiated cells that make up a
body fluid is called the multicellular transcriptome. These
genes comprise ubiquitously expressed housekeeping genes,
which are responsible for cell maintenance functions, and
genes that are specifically expressed in certain tissues only.
The mRNA molecules are present in different quantities
depending on the particular species of mRNA and the cell
type, and can be classified as abundant, moderately abundant
and rare. Although the present invention is dependent on the
identification of tissue-specific mRNA molecules, it is not to
be considered a limitation of the invention. As previously
discussed, tissue-specific genes are still in the process of
being identified.
In addition to identifying two body fluid-specific genes for
each of four body fluids, the present invention provides a
body fluid identification system or method. A number of
design factors and assay quality controls ensure that the tissue-specific, RT-PCR assays disclosed herein detect mRNA
and not genomic DNA.
The two body fluid-specific genes for each of four body
fluids that are the subject of the present invention, are identified in Table I below.

30

BODY FLUIDS
BLOOD
BLOOD

SALIVA
SALIVA
SEMEN
SEMEN
VAGINAL
SECRETIONS
VAGINAL
SECRETIONS

human betadefensin 1
(HBDl)

Fluorescent dye-labeled primers for the eight genes identified above, are incorporated into a single multiplexed polymerase chain reaction (PCR). Following amplification, the
PCR product is separated according to size with capillary
electrophoresis and detected using laser induced fluorescence. The resulting profile, or collection of specific peaks on
the electropherogram that represent the body fluid-specific
genes, identify the body fluids that are present in the sample
as a single or mixed stain. For this invention, the body fluids
include, but are not limited to, blood, saliva, semen or vaginal
secretions.
The following example provides further explanation of the
present invention.
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A physiological stain is prepared by collecting human
blood via venipuncture; collecting 50 micro liter (µl) aliquots
placed onto cotton gauze and dried at room temperature.
Freshly ejaculated semen is collected in plastic cups, and
allowed to dry onto cotton swabs at room temperature. Buccal
scrapings and saliva samples were obtained on cotton swabs,
and dried at room temperature. Vaginal secretions, such as
menstrual blood, are also obtained and dried at room temperature. For RNA or DNA isolation a 50 microliter (µl) blood
or saliva stain, or a single semen, vaginal secretion, or menses
blood stained cotton swab is used.
For RNA isolation, total RNA is extracted from blood,
saliva, vaginal and semen stains with a denaturing solution,
such as, guanidine isothiocyanate-phenol:chloroform and
precipitated with isopropanol. Next, the extracted total RNA
is treated with an enzyme, deoxyribonuclease I (DNase I),
and then reverse-transcribed using random decamers as the
first strand primer, producing complementary DNA (cDNA).
Finally, the cDNA is amplified using gene-specific primers.
The RT-PCR amplimer sizes are carefully chosen to span the
range of approximately 100 base pairs to approximately 300
base pairs, wherein base pairs is the size of amplified product,
to allow facile separation by standard electrophoresis on agarose gels or by capillary electrophoresis.
The primers are custom synthesized commercially. Primers for PBGD, PRMl, and PRM2 are described by A. N.
Gubin and J. L. Miller, in "Human erythroid porphobilinogen
deaminase exists in 2 splice variants." Blood, 97 (2001) pages
815-817, and K. Steger, K. Pauls, T. Klonisch, F. E. Franke
and. M. Bergmann, "Expression of Protamine-1 and -2

US 7,582,435 B2
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mRNA during human spermiogenesis" Mal. Hum. Reprod. 6
(2000) 219-225. The primer sequences (and expected product
sizes) are shown in FIG. 1. The assay of the present invention,
includes, but is not limited to, the primer sequences listed
herein. A person skilled in the, art will readily recognize that
it is possible to redesign primers for one or more of the genes
and it is understood that the redesigned primers are within the
scope of the present invention.
The multiplex PCR reaction mixture contains buffer (10
mM Tris-HCI, pH 8.3, 50 mM KC!), 3.5 mM MgCl 2 , 0.125
mM each dNTP, 5.48 µM PCRprimers (see above), and 1.25
units of DNA Polymerase. The PCR primer pairs are added in
the following concentrations: SPTB, 0.8 µM; PBGD, 0.24
µM, STATH, 0.4 µM; HTN3. 0.4 µM; PRMl, 0.04 µM;
PRM2, 0.4 µM; HBD-1, 1.6 µM; MUC4, 1.6 µM. The standard PCR conditions used for the multiplex consists of a
denaturing step (95° C., 11 min) followed by 35 cycles (94°
C., 20 sec; 55° C., 30 sec; 72° C., 40 sec) and a final extension
step (72° C., 5 min) using a thermocycler instrument.
Based on the above extraction and separation techniques, a
multiplex RT-PCR assay is developed for the definitive identification of all of the body fluids commonly encountered in
forensic casework analysis, namely blood, saliva, semen and
vaginal secretions. The octaplex is composed of eight body
fluid-specific genes and has been optimized for the detection
of blood, saliva, semen, and vaginal secretions as single or

mixed stains. The methodology is based on gene expression
profiling analysis in which the body fluid-specific genes are
identified by detecting the presence of appropriate mRNA
species. The gene-specific primers are labeled with fluorescent dyes (such as Tet or Hex or Fam as indicated in FIG. 1)
incorporated into a single multiplexed polymerase chain
reaction (PCR). The cDNA is amplified using PCR, and the
PCR product is separated according to size using a capillary
electrohoresis instrument, and detected using laser induced
fluorescence. The resulting profile identifies those body fluids
present in a single or mixed stain.
Advantages of the mRNA-based approach, compared to
conventional biochemical analysis include, but are not limited to, greater specificity, simultaneous and semi-automated
analysis through a common assay format, improved timeliness, decreased sample consumption and compatibility with
DNA extraction methodologies. While the invention has been
described, disclosed, illustrated and shown in various terms
of certain embodiments or modifications which it has presumed in practice, the scope of the invention is not intended to
be, nor should it be deemed to be, limited thereby and such
other modifications or embodiments as may be suggested by
the teachings herein are particularly reserved especially as
they fall within the breadth and scope of the claims here
appended.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 16
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 1
aggatggctt ggcctttaat

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 2
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 2
actgccagca ccttcatctt

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 3
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 3
tggatccctga ggagggcaga ag

<210> SEQ ID NO 4

23

US 7,582,435 B2

8

7
-continued
<211>
<212>
<213>
<220>
<223>

LENGTH, 28
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE, 4

tcttgtcccc tgtggtggac atagcaat

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH, 19
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE,

5

cttctgtagt ctcatcttg

<210>
<211>
<212>
<213>
<220>
<223>

28

19

SEQ ID NO 6
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE,

tggttgtggg tatagtggtt gttc

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE,

7

gcaaagagac atcatgggta

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 8
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE,

8

gccagtcaaa cctccataat c

<210>
<211>
<212>
<213>
<220>
<223>

24

21

SEQ ID NO 9
LENGTH, 23
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE,

9

gccaggtaca gatgctgtcg cag

<210> SEQ ID NO 10
<211> LENGTH, 24

23

US 7,582,435 B2
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10
-continued

<212>
<213>
<220>
<223>

TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 10
ttagtgtctt ctacatctcg gtct

<210>
<211>
<212>
<213>
<220>
<223>

24

SEQ ID NO 11
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 11
gtgaggagcc tgagcgaacg c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 12
LENGTH, 25
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 12
ttagtgcctt ctgcatgttc tcttc

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 13
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 13
ttcctgaaat cctgagtgtt

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 14
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 14
taacaggtgc cttgaatttt

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 15
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer

<400> SEQUENCE, 15
ggaccacatt ttatcaggaa

<210> SEQ ID NO 16
<211> LENGTH, 20
<212> TYPE, DNA

20

US 7,582,435 B2
11

12
-continued

<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
primer
<400> SEQUENCE, 16
tagagaaaca gggcatagga

We claim:
1. A kit for use in performing a multiplex, parallel PCR
assay to identify the source of body fluids from a human
being, selected from the group consisting of one or more of
blood, saliva, semen and vaginal secretions, consisting of
PCR primer pairs selected from the group consisting of
5'-agg-atg-gct-tgg-cct-tta-at (Seq ID 1), 5'-act-gcc-agc-accttc-atc-tt (Seq ID 2), 5'-tgg-atc-cct-gag-gag-ggc-aga-ag (Seq
ID 3), 5'-tct-tgt-ccc-ctg-tgg-tgg-aca-tag-caa-t (Seq ID 4),
5'-ctt-ctg-tag-tct-cat-ctt-g (Seq ID 5), 5'-tgg-ttg-tgg-gta-tagtgg-ttg-ttc (Seq ID 6), 5'-gca-aag-aga-cat-cat-ggg-ta (Seq ID
7), 5'-gcc-agt-caa-acc-tcc-ata-atc (Seq 133 8), 5'-gcc-aggtac-aga-tgc-tgt-cgc-ag (Seq ID 9), 5'-tta-gtg-tct-tct-aca-tctcgg-tct (Seq ID 10), 5'-gtg-agg-agc-ctg-agc-gaa-cgc (Seq ID
11 ), 5'-tta-gtg-cct-tct-gca-tgt-tct-ctt-c (Seq ID 12), 5'-tcc-ctgaaa-tcc-tga-gtg-tt (Seq ID 13), 5'-taa-cag-gtg-cct-tga-att-tt
(Seq ID 14), 5'-gga-cca-cat-m-atc-agg-aa (Seq ID 15), 5'-tcgaga-aac-agg-gca-tag-ga (Seq ID 16).
2. A kit, as in claim 1, wherein said primers are tagged with
fluorescent dyes.
3. A kit, as in claim 1, wherein the primers for identifying
the source of body fluids consist of one or more of the group
consisting of (SPTB primers) 5'-agg-atg-gct-tgg-cct-tta-at
(Seq ID 1), 5'-act-gcc-agc-acc-ttc-atc-tt (Seq ID 2), (STATH
primers) 5'-ctt-ctg-tag-tct-cat-ctt-g (Seq ID 5), 5'-tgg-ttg-tgggta-tag-tgg-ttg-ttc (Seq ID 6), (HTN3 primers) 5'-gca-aagaga-cat-cat-ggg-ta (Seq ID 7), 5'-gcc-agt-caa-aac-tcc-ata-atc
(Seq ID 8), (HBD-1 primers) 5'-ttc-ctg-aaa-tcc-tga-gtg-tt
(Seq ID 13), 5'-taa-cag-gtg-cct-tga-att-tt (Seq ID 14), (MUC4
primers) 5'-gga-cca-cat-m-atc-agg-aa (Seq ID 15), 5'-tagaga-aac-agg-gca-tag-ga (Seq ID 16).
4. A kit, as in claim 3, wherein SPTB primer 5'-agg-atggct-tgg-cct-tta-at (Seq ID 1) is labeled with 6-FAM, PBGD
primer 5'-tgg-atc-cct-gag-gag-ggc-aga-ag (Seq ID 3) is
labeled with TET, STATH primer 5'-ctt-ctg-tag-tct-cat-ctt-g
(Seq ID 5) is labeled with 6-FAM, HTN3 primer 5'-gca-aagaga-cat-cat-ggg-ta (Seq ID 7) is labeled with 6-FAM, PRMl
primer 5'-gcc-agg-tac-aga-tgc-tgt-cgc-ag (Seq ID 9) is
labeled with HEX, PRM2 primer 5'-gtg-agg-agc-ctg-agc-
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gaa-cgc (Seq ID 11) is labeled with 6-FAM, HBD-1 primer
5'-ttc-ctg-aaa-tcc-tga-gtg-tt (Seq ID 13) is labeled with
6-FAM, and MUC4 primer 5'-gga-cca-cat-ttt-atc-agg-aa (Seq
ID 15) is labeled with HEX.
5. A kit, as in claim 3, wherein said PCR primers are tagged
with fluorescent dyes.
6. A kit, as in claim 1, wherein said kit further comprises an
enzyme to facilitate a PCR reaction.
7. A kit, as in claim 6, wherein said enzymes is DNA
Polymerase.
8. A kit, as in claim 6, further comprising buffers designed
to facilitate said multiple parallel assay.
9. A kit, as in claim 8, wherein said buffer comprises 10
mM Tris-HCl, pH 8.3, 50 mMKCl, and 1.5 mM MgC12.
10. Primers for identifying the source of body fluids consisting of one or more of the group consisting of, (STATH
primers) 5'-ctt-ctg-tag-tct-cat-ctt-g (Seq ID 5), 5'-tgg-ttg-tgggta-tag-tgg-ttg-ttc (Seq ID 6), (HTN3 primers) 5'-gca-aagaga-cat-cat-ggg-ta (Seq ID 7), 5'-gcc-agt-caa-acc-tcc-ata-atc
(Seq ID 8), (HBD-1 primers) 5'-ttc-ctg-aaa-tcc-tga-gtg-tt
(Seq ID 13), 5'-taa-cag-gtg-cct-tga-att-tt (Seq ID 14), (MUC4
primers) 5'-gga-cca-cat-m-atc-agg-aa (Seq ID 15), 5'-tagaga-aac-agg-gca-tag-ga (Seq ID 16).
11. The Primers for identifying the source of body fluids as
in claim 10, wherein said primers are tagged with fluorescent
dyes.
12. Primers for identifying the source of body fluids as
wherein PBGD primer 5'-tgg-atc-cct-gag-gag-ggc-aga-ag
(Seq ID 3) is labeled with TET, STATH primer 5'-ctt-ctg-tagtct-cat-ctt-g (Seq ID 5) is labeled with 6-FAM, HTN3 primer
5'-gca-aag-aga-cat-cat-ggg-ta (Seq ID 7) is labeled with
6-FAM, PRMl primer 5'-gcc-agg-tac-aga-tgc-tgt-cgc-ag
(Seq ID 9) is labeled with HEX, PRM2 primer 5'-gtg-aggagc-ctg-agc-gaa-cgc (Seq ID 11) is labeled with 6-FAM,
HBD-1 primer 5'-ttc-ctg-aaa-tcc-tga-gtg-tt (Seq ID 13) is
labeled with 6-FAM, and MUC4 primer 5'-gga-cca-cat-matc-agg-aa (Seq ID 15) is labeled with HEX.
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